Special Issue "Advances of PET-CT Imaging in Oncology"

A special issue of Tomography (ISSN 2379-139X). This special issue belongs to the section "Cancer Imaging".

Deadline for manuscript submissions: 31 December 2022 | Viewed by 1136

Special Issue Editor

Dr. Gaetano Paone
E-Mail Website
Guest Editor
Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
Interests: PET/CT; hybrid imaging; theragnostic; therapy monitoring based on PET criteria; functional PET parameters; personalized dosimetry

Special Issue Information

Dear Colleagues,

Over the last decade, molecular imaging has remarkably improved the monitoring and management of oncological patients. In particular, PET-CT is a sensitive imaging modality that represents one of the pillars of molecular imaging in oncology, and has become fundamental for response evaluation in several tumor types. We are entering an exciting new era where innovations in PET-CT may bring new clinical opportunities and therapeutic strategies.

This Special Issue aims to summarize the most promising clinical applications and improvements in PET-CT imaging. Original research articles and reviews with particular interest in PET-based treatment response and PET applications in the theragnostic field are welcome, emphasizing (but not limited to) the present and future role of PET-CT imaging in prognosis, treatment response and disease relapse in oncology.

We look forward to receiving your contributions.

Dr. Gaetano Paone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tomography is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PET/CT
  • treatment response
  • oncology
  • theragnostic

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

Article
Relationship between Baseline [18F]FDG PET/CT Semiquantitative Parameters and BRCA Mutational Status and Their Prognostic Role in Patients with Invasive Ductal Breast Carcinoma
Tomography 2022, 8(6), 2662-2675; https://doi.org/10.3390/tomography8060222 - 27 Oct 2022
Viewed by 404
Abstract
Aim: To assess the relationship between [18F]FDG PET/CT, breast cancer gene (BRCA) status, and their prognostic role in patients with ductal breast cancer (DBC). Methods: Forty-one women were included. PET/CT semiquantitative parameters such as standardized uptake value (SUV) body weight max [...] Read more.
Aim: To assess the relationship between [18F]FDG PET/CT, breast cancer gene (BRCA) status, and their prognostic role in patients with ductal breast cancer (DBC). Methods: Forty-one women were included. PET/CT semiquantitative parameters such as standardized uptake value (SUV) body weight max (SUVmax), SUV body weight mean (SUVmean), SUV lean body mass (SUVlbm), SUV body surface area (SUVbsa), metabolic tumor volume (MTV), total lesion glycolysis (TLG), ratio SUVmax/blood-pool (S-BP), and ratio SUVmax/liver (S-L) were also extracted. The relationship between these parameters, BRCA, and other clinicopathological features were evaluated. Kaplan–Meier, univariate, and multivariate analyses were performed to find independent prognosticators for progression free (PFS) and overall survival (OS). Results: Significant positive correlations between BRCA status and SUVmax (p-value 0.025), SUVlbm (p-value 0.016), and SUVbsa (p-value 0.018) were reported. Mean PFS was 53.90 months with relapse/progression of disease occurring in nine (22.0%) patients; mean OS was 57.48 months with death occurring in two (4.9%) patients. Survival curves revealed TLG, MTV, and BRCA status as prognosticator for PFS; BRCA was also a prognosticator for OS. Univariate and multivariate analyses did not confirm such insights. Conclusion: We reported a correlation between some PET/CT parameters and BRCA status; some insights on their prognostic role have been underlined. Full article
(This article belongs to the Special Issue Advances of PET-CT Imaging in Oncology)
Show Figures

Figure 1

Other

Jump to: Research

Case Report
Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT
Tomography 2022, 8(5), 2471-2474; https://doi.org/10.3390/tomography8050205 - 30 Sep 2022
Viewed by 569
Abstract
For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging technique by the European Association of Urology (EAU) guidelines is prostate-specific membrane antigen (PSMA) positron emission tomography/computer tomography (PET/CT). Indeed, the increased detection rate of PSMA PET/CT for early BCR has led [...] Read more.
For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging technique by the European Association of Urology (EAU) guidelines is prostate-specific membrane antigen (PSMA) positron emission tomography/computer tomography (PET/CT). Indeed, the increased detection rate of PSMA PET/CT for early BCR has led to a fast and wide acceptance of this novel technology. However, PCa is a very heterogeneous disease, not always easily assessable with the highly specific PSMA PET with around 10% of cases occuring without PSMA expression. In this paper, we present the case of a patient with PCa BCR that resulted negative on [68Ga]Ga-PSMA-11 PET/CT, but positive on [18F]Fluoromethylcholine (Choline) PET/CT. Full article
(This article belongs to the Special Issue Advances of PET-CT Imaging in Oncology)
Show Figures

Figure 1

Back to TopTop